{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T18:19:26Z","timestamp":1783361966204,"version":"3.54.6"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Science Centre, Poland","award":["UMO-2018\/31\/D\/NZ5\/01754"],"award-info":[{"award-number":["UMO-2018\/31\/D\/NZ5\/01754"]}]},{"name":"National Science Centre, Poland","award":["UMO-2018\/31\/D\/NZ5\/01754"],"award-info":[{"award-number":["UMO-2018\/31\/D\/NZ5\/01754"]}]},{"name":"National Science Centre, Poland","award":["UMO-2018\/31\/D\/NZ5\/01754"],"award-info":[{"award-number":["UMO-2018\/31\/D\/NZ5\/01754"]}]},{"name":"National Science Centre, Poland","award":["UMO-2018\/31\/D\/NZ5\/01754"],"award-info":[{"award-number":["UMO-2018\/31\/D\/NZ5\/01754"]}]},{"name":"National Science Centre, Poland","award":["UMO-2018\/31\/D\/NZ5\/01754"],"award-info":[{"award-number":["UMO-2018\/31\/D\/NZ5\/01754"]}]},{"name":"National Science Centre, Poland","award":["UMO-2018\/31\/D\/NZ5\/01754"],"award-info":[{"award-number":["UMO-2018\/31\/D\/NZ5\/01754"]}]},{"name":"National Science Centre, Poland","award":["UMO-2018\/31\/D\/NZ5\/01754"],"award-info":[{"award-number":["UMO-2018\/31\/D\/NZ5\/01754"]}]},{"name":"National Science Centre, Poland","award":["UMO-2018\/31\/D\/NZ5\/01754"],"award-info":[{"award-number":["UMO-2018\/31\/D\/NZ5\/01754"]}]},{"name":"National Science Centre, Poland","award":["UMO-2018\/31\/D\/NZ5\/01754"],"award-info":[{"award-number":["UMO-2018\/31\/D\/NZ5\/01754"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-03943-2","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T14:01:11Z","timestamp":1738418471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Normalization of tumor vasculature by imiquimod: proposal for a new anticancer therapeutic indication for a TLR7 agonist"],"prefix":"10.1007","volume":"74","author":[{"given":"Jarosz-Biej","family":"Magdalena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Czapla","family":"Justyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciep\u0142a","family":"Joanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smolarczyk","family":"Ryszard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drzyzga","family":"Alina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sprus-Lipka","family":"Dorota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilny","family":"Ewelina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matuszczak","family":"Sybilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cicho\u0144","family":"Tomasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"key":"3943_CR1","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA (2023) The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell 41:374\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.016","journal-title":"Cancer Cell"},{"key":"3943_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174444","author":"K Matuszewska","year":"2021","unstructured":"Matuszewska K, Pereira M, Petrik D, Lawler J, Petrik J (2021) Normalizing tumor vasculature to reduce hypoxia, enhance perfusion, and optimize therapy uptake. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13174444","journal-title":"Cancers (Basel)"},{"key":"3943_CR3","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41416-021-01330-z","volume":"125","author":"AL Magnussen","year":"2021","unstructured":"Magnussen AL, Mills IG (2021) Vascular normalisation as the stepping stone into tumour microenvironment transformation. Br J Cancer 125:324\u2013336. https:\/\/doi.org\/10.1038\/s41416-021-01330-z","journal-title":"Br J Cancer"},{"key":"3943_CR4","doi-asserted-by":"publisher","first-page":"1291530","DOI":"10.3389\/fimmu.2023.1291530","volume":"14","author":"C Qian","year":"2023","unstructured":"Qian C, Liu C, Liu W, Zhou R, Zhao L (2023) Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy. Front Immunol 14:1291530. https:\/\/doi.org\/10.3389\/fimmu.2023.1291530","journal-title":"Front Immunol"},{"key":"3943_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z, Han F, Du Y, Shi H, Zhou W (2023) Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther 8:70. https:\/\/doi.org\/10.1038\/s41392-023-01332-8","journal-title":"Signal Transduct Target Ther"},{"key":"3943_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-50287-4_22","author":"M Jarosz-Biej","year":"2020","unstructured":"Jarosz-Biej M, Smolarczyk R, Cicho\u0144 T, Szala S (2020) Reprogramming of tumor microenvironment in therapy. Cancer Immunol: Bench to Bedside Immunotherapy of Cancers. https:\/\/doi.org\/10.1007\/978-3-030-50287-4_22","journal-title":"Cancer Immunol: Bench to Bedside Immunotherapy of Cancers"},{"key":"3943_CR7","doi-asserted-by":"publisher","first-page":"719836","DOI":"10.3389\/fonc.2021.719836","volume":"11","author":"T Yang","year":"2021","unstructured":"Yang T, Xiao H, Liu X, Wang Z, Zhang Q, Wei N, Guo X (2021) Vascular normalization: a new window opened for cancer therapies. Front Oncol 11:719836. https:\/\/doi.org\/10.3389\/fonc.2021.719836","journal-title":"Front Oncol"},{"key":"3943_CR8","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","volume":"91","author":"S Goel","year":"2011","unstructured":"Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91:1071\u20131121. https:\/\/doi.org\/10.1152\/physrev.00038.2010","journal-title":"Physiol Rev"},{"key":"3943_CR9","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1038\/s12276-023-01114-w","volume":"55","author":"Y Choi","year":"2023","unstructured":"Choi Y, Jung K (2023) Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy. Exp Mol Med 55:2308\u20132319. https:\/\/doi.org\/10.1038\/s12276-023-01114-w","journal-title":"Exp Mol Med"},{"key":"3943_CR10","doi-asserted-by":"publisher","first-page":"109167","DOI":"10.1016\/j.intimp.2022.109167","volume":"112","author":"X Luo","year":"2022","unstructured":"Luo X, Zou W, Wei Z, Yu S, Zhao Y, Wu Y, Wang A, Lu Y (2022) Inducing vascular normalization: a promising strategy for immunotherapy. Int Immunopharmacol 112:109167. https:\/\/doi.org\/10.1016\/j.intimp.2022.109167","journal-title":"Int Immunopharmacol"},{"key":"3943_CR11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1023\/b:appt.0000025805.55340.c3","volume":"9","author":"MP Schon","year":"2004","unstructured":"Schon MP, Schon M (2004) Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 9:291\u2013298. https:\/\/doi.org\/10.1023\/b:appt.0000025805.55340.c3","journal-title":"Apoptosis"},{"key":"3943_CR12","doi-asserted-by":"publisher","first-page":"1049340","DOI":"10.3389\/fimmu.2022.1049340","volume":"13","author":"Y Yang","year":"2022","unstructured":"Yang Y, Li H, Fotopoulou C, Cunnea P, Zhao X (2022) Toll-like receptor-targeted anti-tumor therapies: Advances and challenges. Front Immunol 13:1049340. https:\/\/doi.org\/10.3389\/fimmu.2022.1049340","journal-title":"Front Immunol"},{"key":"3943_CR13","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3892\/ol.2017.6235","volume":"14","author":"T Karashima","year":"2017","unstructured":"Karashima T, Udaka K, Niimura M et al (2017) Therapy with transcutaneous administration of imiquimod combined with oral administration of sorafenib suppresses renal cell carcinoma growing in an orthotopic mouse model. Oncol Lett 14:1162\u20131166. https:\/\/doi.org\/10.3892\/ol.2017.6235","journal-title":"Oncol Lett"},{"key":"3943_CR14","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.21873\/anticanres.11714","volume":"37","author":"S Furudate","year":"2017","unstructured":"Furudate S, Fujimura T, Kambayashi Y, Kakizaki A, Hidaka T, Aiba S (2017) Immunomodulatory effect of imiquimod through CCL22 produced by tumor-associated macrophages in B16F10 melanomas. Anticancer Res 37:3461\u20133471. https:\/\/doi.org\/10.21873\/anticanres.11714","journal-title":"Anticancer Res"},{"key":"3943_CR15","doi-asserted-by":"publisher","first-page":"6748","DOI":"10.1158\/1078-0432.CCR-12-1149","volume":"18","author":"S Adams","year":"2012","unstructured":"Adams S, Kozhaya L, Martiniuk F et al (2012) Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res 18:6748\u20136757. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1149","journal-title":"Clin Cancer Res"},{"key":"3943_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310835","author":"E Garcia-Mouronte","year":"2023","unstructured":"Garcia-Mouronte E, Berna-Rico E, de Nicolas-Ruanes B, Azcarraga-Llobet C, Alonso-Martinez de Salinas L, Bea-Ardebol S (2023) Imiquimod as local immunotherapy in the management of premalignant cutaneous conditions and skin cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241310835","journal-title":"Int J Mol Sci"},{"key":"3943_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nrc3958","volume":"15","author":"HE Barker","year":"2015","unstructured":"Barker HE, Paget JT, Khan AA, Harrington KJ (2015) The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer 15:409\u2013425. https:\/\/doi.org\/10.1038\/nrc3958","journal-title":"Nat Rev Cancer"},{"key":"3943_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/cam4.402","volume":"4","author":"AS Pandit","year":"2015","unstructured":"Pandit AS, Geiger EJ, Ariyan S, Narayan D, Choi JN (2015) Using topical imiquimod for the management of positive in situ margins after melanoma resection. Cancer Med 4:507\u2013512. https:\/\/doi.org\/10.1002\/cam4.402","journal-title":"Cancer Med"},{"key":"3943_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ccr.2010.11.009","volume":"19","author":"C Rolny","year":"2011","unstructured":"Rolny C, Mazzone M, Tugues S et al (2011) HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19:31\u201344. https:\/\/doi.org\/10.1016\/j.ccr.2010.11.009","journal-title":"Cancer Cell"},{"key":"3943_CR20","doi-asserted-by":"publisher","first-page":"173692","DOI":"10.1016\/j.ejphar.2020.173692","volume":"891","author":"R Smolarczyk","year":"2021","unstructured":"Smolarczyk R, Czapla J, Jarosz-Biej M, Czerwinski K, Cichon T (2021) Vascular disrupting agents in cancer therapy. Eur J Pharmacol 891:173692. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173692","journal-title":"Eur J Pharmacol"},{"key":"3943_CR21","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.7150\/thno.22610","volume":"8","author":"J Epah","year":"2018","unstructured":"Epah J, Palfi K, Dienst FL et al (2018) 3D imaging and quantitative analysis of vascular networks: a comparison of ultramicroscopy and micro-computed tomography. Theranostics 8:2117\u20132133. https:\/\/doi.org\/10.7150\/thno.22610","journal-title":"Theranostics"},{"key":"3943_CR22","doi-asserted-by":"publisher","first-page":"e0191012","DOI":"10.1371\/journal.pone.0191012","volume":"13","author":"M Jarosz-Biej","year":"2018","unstructured":"Jarosz-Biej M, Kaminska N, Matuszczak S et al (2018) M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma. PLoS ONE 13:e0191012. https:\/\/doi.org\/10.1371\/journal.pone.0191012","journal-title":"PLoS ONE"},{"key":"3943_CR23","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/gt.2012.28","volume":"20","author":"M Jarosz","year":"2013","unstructured":"Jarosz M, Jazowiecka-Rakus J, Cichon T, Glowala-Kosinska M, Smolarczyk R, Smagur A, Malina S, Sochanik A, Szala S (2013) Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents. Gene Ther 20:262\u2013273. https:\/\/doi.org\/10.1038\/gt.2012.28","journal-title":"Gene Ther"},{"key":"3943_CR24","doi-asserted-by":"publisher","first-page":"790952","DOI":"10.3389\/fphar.2021.790952","volume":"12","author":"P Pantziarka","year":"2021","unstructured":"Pantziarka P, Vandeborne L, Bouche G (2021) A database of drug repurposing clinical trials in oncology. Front Pharmacol 12:790952. https:\/\/doi.org\/10.3389\/fphar.2021.790952","journal-title":"Front Pharmacol"},{"key":"3943_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","volume":"9","author":"Y Xia","year":"2024","unstructured":"Xia Y, Sun M, Huang H, Jin WL (2024) Drug repurposing for cancer therapy. Signal Transduct Target Ther 9:92. https:\/\/doi.org\/10.1038\/s41392-024-01808-1","journal-title":"Signal Transduct Target Ther"},{"key":"3943_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020385","author":"S Hirobe","year":"2022","unstructured":"Hirobe S, Yamasaki T, Ito S, Quan YS, Kamiyama F, Tachibana M, Okada N (2022) Transcutaneous administration of imiquimod promotes T and B cell differentiation into effector cells or plasma cells. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics14020385","journal-title":"Pharmaceutics"},{"key":"3943_CR27","doi-asserted-by":"publisher","first-page":"100482","DOI":"10.1016\/j.mtbio.2022.100482","volume":"17","author":"YH Wen","year":"2022","unstructured":"Wen YH, Hsieh PI, Chiu HC, Chiang CW, Lo CL, Chiang YT (2022) Precise delivery of doxorubicin and imiquimod through pH-responsive tumor microenvironment-active targeting micelles for chemo- and immunotherapy. Mater Today Bio 17:100482. https:\/\/doi.org\/10.1016\/j.mtbio.2022.100482","journal-title":"Mater Today Bio"},{"key":"3943_CR28","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.biopha.2018.04.079","volume":"103","author":"MF Dias","year":"2018","unstructured":"Dias MF, Figueiredo BCP, Teixeira-Neto J, Guerra MCA, Fialho SL, Silva Cunha A (2018) In vivo evaluation of antitumoral and antiangiogenic effect of imiquimod-loaded polymeric nanoparticles. Biomed Pharmacother 103:1107\u20131114. https:\/\/doi.org\/10.1016\/j.biopha.2018.04.079","journal-title":"Biomed Pharmacother"},{"key":"3943_CR29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jconrel.2022.10.053","volume":"352","author":"H Liu","year":"2022","unstructured":"Liu H, Wen Z, Chen H, Yang Z, Le Z, Liu Z, Chen Y, Liu L (2022) Nanoadjuvants actively targeting lymph node conduits and blocking tumor invasion in lymphatic vessels. J Control Release 352:497\u2013506. https:\/\/doi.org\/10.1016\/j.jconrel.2022.10.053","journal-title":"J Control Release"},{"issue":"39","key":"3943_CR30","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.urolonc.2016.09.006","volume":"35","author":"NM Donin","year":"2017","unstructured":"Donin NM, Chamie K, Lenis AT et al (2017) A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. Urol Oncol 35(39):e1\u2013e7. https:\/\/doi.org\/10.1016\/j.urolonc.2016.09.006","journal-title":"Urol Oncol"},{"key":"3943_CR31","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jdermsci.2022.08.006","volume":"107","author":"SH Chang","year":"2022","unstructured":"Chang SH, Lin PY, Wu TK et al (2022) Imiquimod-induced ROS production causes lysosomal membrane permeabilization and activates caspase-8-mediated apoptosis in skin cancer cells. J Dermatol Sci 107:142\u2013150. https:\/\/doi.org\/10.1016\/j.jdermsci.2022.08.006","journal-title":"J Dermatol Sci"},{"key":"3943_CR32","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1634\/theoncologist.2008-0097","volume":"13","author":"EL Smits","year":"2008","unstructured":"Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF (2008) The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13:859\u2013875. https:\/\/doi.org\/10.1634\/theoncologist.2008-0097","journal-title":"Oncologist"},{"key":"3943_CR33","doi-asserted-by":"publisher","first-page":"6668","DOI":"10.1158\/1078-0432.CCR-12-0984","volume":"18","author":"MZ Dewan","year":"2012","unstructured":"Dewan MZ, Vanpouille-Box C, Kawashima N, DiNapoli S, Babb JS, Formenti SC, Adams S, Demaria S (2012) Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res 18:6668\u20136678. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0984","journal-title":"Clin Cancer Res"},{"key":"3943_CR34","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00262-016-1880-z","volume":"65","author":"IS Mauldin","year":"2016","unstructured":"Mauldin IS, Wages NA, Stowman AM et al (2016) Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. Cancer Immunol Immunother 65:1201\u20131212. https:\/\/doi.org\/10.1007\/s00262-016-1880-z","journal-title":"Cancer Immunol Immunother"},{"key":"3943_CR35","doi-asserted-by":"publisher","first-page":"e1027473","DOI":"10.1080\/2162402X.2015.1027473","volume":"4","author":"S Lunardi","year":"2015","unstructured":"Lunardi S, Lim SY, Muschel RJ, Brunner TB (2015) IP-10\/CXCL10 attracts regulatory T cells: implication for pancreatic cancer. Oncoimmunology 4:e1027473. https:\/\/doi.org\/10.1080\/2162402X.2015.1027473","journal-title":"Oncoimmunology"},{"key":"3943_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cells12040659","author":"M Kciuk","year":"2023","unstructured":"Kciuk M, Gielecinska A, Mujwar S, Kolat D, Kaluzinska-Kolat Z, Celik I, Kontek R (2023) Doxorubicin-an agent with multiple mechanisms of anticancer activity. Cells. https:\/\/doi.org\/10.3390\/cells12040659","journal-title":"Cells"},{"key":"3943_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040740","author":"F Liotti","year":"2021","unstructured":"Liotti F, Marotta M, Sorriento D, Pone E, Morra F, Melillo RM, Prevete N (2021) Toll-like receptor 7 mediates inflammation resolution and inhibition of angiogenesis in non-small cell lung cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13040740","journal-title":"Cancers (Basel)"},{"key":"3943_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1365-4632.2004.02318.x","volume":"44","author":"S Majewski","year":"2005","unstructured":"Majewski S, Marczak M, Mlynarczyk B, Benninghoff B, Jablonska S (2005) Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Int J Dermatol 44:14\u201319. https:\/\/doi.org\/10.1111\/j.1365-4632.2004.02318.x","journal-title":"Int J Dermatol"},{"key":"3943_CR39","doi-asserted-by":"publisher","unstructured":"Zhao Y, Zhang T, Wang Y et al. (2021) ICAM-1 orchestrates the abscopal effect of tumor radiotherapy. Proceedings of the National Academy of Sciences U S A. 118. https:\/\/doi.org\/10.1073\/pnas.2010333118","DOI":"10.1073\/pnas.2010333118"},{"key":"3943_CR40","doi-asserted-by":"publisher","first-page":"24932","DOI":"10.18632\/oncotarget.15326","volume":"8","author":"JH Cho","year":"2017","unstructured":"Cho JH, Lee HJ, Ko HJ et al (2017) The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma. Oncotarget 8:24932\u201324948. https:\/\/doi.org\/10.18632\/oncotarget.15326","journal-title":"Oncotarget"}],"updated-by":[{"DOI":"10.1007\/s00262-025-04062-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000}}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-03943-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-03943-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-03943-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:02:30Z","timestamp":1748361750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-03943-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["3943"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-03943-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00262-025-04062-8","asserted-by":"object"}]},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00262-025-04062-8","URL":"https:\/\/doi.org\/10.1007\/s00262-025-04062-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Studies on mice were performed according to the protocols approved by the Local Ethics Committee for Animal Experiments in Katowice (Permit Number: 21\/2020, 50A\/2023, 50B\/2023, 50D\/2023).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"90"}}